[Pneumocystis jiroveci pneumonia during infliximab therapy].
The treatment of ulcerative colitis has improved since the appearance of Tumor Necrosis Factor (TNF)-alpha inhibitors. However, the use of TNF-alpha inhibitors increases the risk of opportunistic infections. We describe two cases of Pneumocystis jiroveci pneumonia during infliximab therapy for active ulcerative colitis. They were successfully treated with sulfametoxazole/trimetroprim. High awareness of P. jiroveci pneumonia in patients who develop pulmonary symptoms with hypoxia during TNF-alpha modulator therapy is recommended.
Josephson
Maria Eklund
ME
Regionshospitalet Viborg, Medicinsk Afdeling, Viborg.
Kristensen
Lena Hagelskjaer
LH
Andersen
Vibeke Charlotte
VC
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000382:microbiology*; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000000981:diagnostic imaging / Q000382:microbiology*; D011350:Proctocolitis / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab